The FDA has approved FocalSeal-L (Focal Inc, Lexington, Mass) for use
in lungs as an adjunct to standard closure of pleural air leaks incurred during
elective pulmonary resection, such as the removal of cancerous lung tumors.
The new product, which received expedited review by the FDA, consists
of synthetic absorbable sealant and primer solutions that are applied to the
target tissue site as liquids. Upon exposure to blue-green light, the primer
and sealant solutions polymerize to form a cross-linked, clear, flexible,
adherent hydrogel network.
Surgical Sealant for Lung Cancer. JAMA. 2000;284(6):685. doi:10.1001/jama.284.6.685
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: